Tetraphase Pharmaceuticals Inc. (TTPH)

0.69
0.04 5.92
NASDAQ : Health Technology
Prev Close 0.66
Open 0.66
Day Low/High 0.65 / 0.70
52 Wk Low/High 0.66 / 4.49
Volume 498.07K
Avg Volume 578.10K
Exchange NASDAQ
Shares Outstanding 54.26M
Market Cap 36.93M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Tetraphase Pharmaceuticals Announces Corporate Reorganization Aimed At Maximizing XERAVA™ (Eravacycline) Commercial Opportunity

Tetraphase Pharmaceuticals Announces Corporate Reorganization Aimed At Maximizing XERAVA™ (Eravacycline) Commercial Opportunity

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), ("Tetraphase" or "the Company") today announced a corporate reorganization in order to maximize the commercial opportunity for XERAVA™ (eravacycline), the Company's novel tetracycline antibacterial indicated...

Tetraphase Pharmaceuticals Announces New XERAVA™ (eravacycline) Data At The 39th Annual Surgical Infection Society Meeting

Tetraphase Pharmaceuticals Announces New XERAVA™ (eravacycline) Data At The 39th Annual Surgical Infection Society Meeting

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced the presentation of positive data from three...

Tetraphase Pharmaceuticals To Present Data At The 39th Annual Meeting Of The Surgical Infection Society

Tetraphase Pharmaceuticals To Present Data At The 39th Annual Meeting Of The Surgical Infection Society

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that data from four abstracts will be presented at...

Tetraphase Pharmaceuticals Reports First Quarter 2019 Financial Results And Highlights Recent Corporate Developments

Tetraphase Pharmaceuticals Reports First Quarter 2019 Financial Results And Highlights Recent Corporate Developments

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions including multidrug-resistant (MDR) infections, today reported...

Tetraphase Pharmaceuticals To Present Data At The 22nd Annual MAD-ID Meeting

Tetraphase Pharmaceuticals To Present Data At The 22nd Annual MAD-ID Meeting

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced five data presentations at the 22 nd Annual MAD-ID...

Tetraphase Pharmaceuticals To Host First Quarter 2019 Financial Results Conference Call

Tetraphase Pharmaceuticals To Host First Quarter 2019 Financial Results Conference Call

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that company management will host a conference call...

Tetraphase Pharmaceuticals To Participate In Upcoming Investor Conferences

Tetraphase Pharmaceuticals To Participate In Upcoming Investor Conferences

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that senior management will be participating at the...

Tetraphase Pharmaceuticals To Present Data At The 29th European Congress Of Clinical Microbiology And Infectious Diseases

Tetraphase Pharmaceuticals To Present Data At The 29th European Congress Of Clinical Microbiology And Infectious Diseases

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced five data presentations at the 29 th European...

Tetraphase Pharmaceuticals Presents Preclinical Data On TP-2846, A Novel Drug Candidate For Acute Myeloid Leukemia

Tetraphase Pharmaceuticals Presents Preclinical Data On TP-2846, A Novel Drug Candidate For Acute Myeloid Leukemia

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced data from its preclinical program for TP-2846, the...

Tetraphase Pharmaceuticals To Present At Upcoming Investor Conferences

Tetraphase Pharmaceuticals To Present At Upcoming Investor Conferences

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that senior management will present a corporate...

Tetraphase Pharmaceuticals Reports Fourth Quarter And Full-Year 2018 Financial Results And Highlights Achievements And Key 2019 Milestones

Tetraphase Pharmaceuticals Reports Fourth Quarter And Full-Year 2018 Financial Results And Highlights Achievements And Key 2019 Milestones

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today reported financial results for the fourth quarter and year...

Tetraphase Pharmaceuticals To Host Fourth Quarter And Full-Year 2018 Financial Results Conference Call

Tetraphase Pharmaceuticals To Host Fourth Quarter And Full-Year 2018 Financial Results Conference Call

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that company management will host a conference call...

Tetraphase Pharmaceuticals To Present Data On Preclinical Activity Of TP-2846 In Acute Myeloid Leukemia

Tetraphase Pharmaceuticals To Present Data On Preclinical Activity Of TP-2846 In Acute Myeloid Leukemia

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat life-threatening conditions, today announced it will present three posters on TP-2846, the Company's newly...

First Week Of August 16th Options Trading For Tetraphase Pharmaceuticals (TTPH)

First Week Of August 16th Options Trading For Tetraphase Pharmaceuticals (TTPH)

Investors in Tetraphase Pharmaceuticals, Inc saw new options begin trading this week, for the August 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 224 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

EQUITY NOTICE: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. - TTPH

EQUITY NOTICE: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. - TTPH

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Tetraphase Pharmaceuticals, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tetraphase Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tetraphase Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Tetraphase Pharmaceuticals, Inc.

Interesting TTPH Call Options For October 19th

Interesting TTPH Call Options For October 19th

Investors in Tetraphase Pharmaceuticals, Inc saw new options begin trading this week, for the October 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TTPH options chain for the new October 19th contracts and identified the following call contract of particular interest.

Robbins Geller Rudman & Dowd LLP Announces A Securities Case Has Been Filed On Behalf Of Purchasers Of Tetraphase Pharmaceuticals, Inc. Securities

Robbins Geller Rudman & Dowd LLP Announces A Securities Case Has Been Filed On Behalf Of Purchasers Of Tetraphase Pharmaceuticals, Inc. Securities

Robbins Geller Rudman & Dowd LLP announces that a securities class action case was filed on behalf of purchasers of Tetraphase Pharmaceuticals, Inc.

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tetraphase Pharmaceuticals, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tetraphase Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tetraphase Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Tetraphase Pharmaceuticals, Inc.

First Week Of November 16th Options Trading For Tetraphase Pharmaceuticals (TTPH)

Investors in Tetraphase Pharmaceuticals, Inc saw new options become available this week, for the November 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 197 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

INVESTOR ALERT: Investigation Of Tetraphase Pharmaceuticals Announced By Holzer & Holzer

INVESTOR ALERT: Investigation Of Tetraphase Pharmaceuticals Announced By Holzer & Holzer

Holzer & Holzer, LLC is investigating whether Tetraphase Pharmaceuticals, Inc.

TheStreet Quant Rating: D (Sell)